LO FRANCIS sold $2.4M of ADPT

LO FRANCIS (Chief People Officer) sold 105,762 shares of Adaptive Biotechnologies Corp (ADPT) at $22.59 ($2.39M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LO FRANCIS
Published Jul 17, 2026, 11:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 11:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The disclosure provides transparency on insider trading activity but does not introduce new company-specific fundamentals or guidance.

02

Market read

Traders may note insider selling activity, but the 10b5-1 designation reduces interpretive weight.

03

What to watch

Insider sales can be offset by other insider purchases or broader company catalysts not mentioned here; this filing alone does not establish directionality for future performance.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-17, reflecting a sale executed 2026-07-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

SEC Form 4 shows Adaptive Biotechnologies insider Lo Francis sold 105,762 shares at $22.59 on 2026-07-15 under a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any effect is more about sentiment than new company information.

Evidence & confidence

The filing is a primary-source Form 4, but it discloses no new operational, financial, or regulatory development, and explicitly notes a pre-arranged 10b5-1 plan.

Market effects

No clear read-across to biotech sector fundamentals from a single insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the Form 4 insider transaction disclosure.

  • Lo Francis

    Chief People Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.